Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus

D'Amico, Ferdinando; Solitano, Virginia; Aletaha, Daniel; Hart, Ailsa; Magro, Fernando; Selmi, Carlo; Ng, Siew C.; Al Awadhi, Sameer; Choy, Ernest; Schulze-Koops, Hendrik; Bossuyt, Peter; Olivera, Pablo A.; Kotze, Paulo Gustavo; Ghosh, Subrata; Peyrin-Biroulet, Laurent und Danese, Silvio (2021): Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. In: Autoimmunity Reviews, Bd. 20, Nr. 7, 102849

Abstract

Several efforts have been made to improve the available therapeutic armamentarium of patients with immunemediated inflammatory disorders (IMIDs) leading to the development of biobetters. To date, there is no commonly accepted definition of biobetters. Sixteen physicians with expertise in the field of IMIDs from eleven countries attended a virtual international consensus meeting to provide for the first time a definition of biobetter and to identify unmet needs on this topic. Improvements in clinical outcomes and drug pharmacology were considered crucial for the definition of biobetters, while safety profile and patient acceptability were not. In addition, an appropriate balance between clinical outcomes and costs and a shared decision between physicians and patients should guide the decision to use a biobetter. Clinical studies are required to validate the biobetter definition and to investigate their role in the management of patients with IMIDs.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1568-9972
• Sprache: Englisch